You are here:

cangrelor (Kengrexal)

Advice

in the absence of a submission from the holder of the marketing authorisation

cangrelor (Kengrexal®) is not recommended for use within NHS Scotland.

Indication under review: Co-administered with acetylsalicylic acid for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: cangrelor (Kengrexal)
SMC Drug ID: 1070/15
Manufacturer: The Medicines Company
Indication: Co-administered with acetylsalicylic acid for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
BNF Category:
Sub Category: 2.9 Antiplatelet drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 8 June 2015

Back